TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04074356

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical measure questionnaires
Description: Collection of patient reported symptoms and perception of health

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical measure questionnaires
Description: Collection of patient reported symptoms and perception of health

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: EESG
Description: Use of silver-silver chloride cutaneous electrogastrogram (EGG) electrodes to get myoelectrical readings

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: EESG
Description: Use of silver-silver chloride cutaneous electrogastrogram (EGG) electrodes to get myoelectrical readings

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: EESG
Description: Use of silver-silver chloride cutaneous electrogastrogram (EGG) electrodes to get myoelectrical readings

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: MESG
Description: MESG measures spatiotemporal properties of magnetic fields from the esophageal slow wave and allows characterization of the propagation of the slow wave in addition to evaluation of its frequency and power distribution

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: MESG
Description: MESG measures spatiotemporal properties of magnetic fields from the esophageal slow wave and allows characterization of the propagation of the slow wave in addition to evaluation of its frequency and power distribution

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: MESG
Description: MESG measures spatiotemporal properties of magnetic fields from the esophageal slow wave and allows characterization of the propagation of the slow wave in addition to evaluation of its frequency and power distribution

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: High resolution manometry (HRM)
Description: Dysphagia subjects will have undergone standard of care HRM to determine placement in the achalasia or hypercontractile/spastic disorder arms

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: High resolution manometry (HRM)
Description: Dysphagia subjects will have undergone standard of care HRM to determine placement in the achalasia or hypercontractile/spastic disorder arms
Study: NCT00318409

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03297801

Intervention type: DIETARY_SUPPLEMENT
Intervention: Fish oil supplements
Description: Women who chose to supplement with fish oil during gestation or lactation.
Study: NCT02404272

Intervention type: OTHER
Intervention: Educational oral feeding nurse program
Description: A multidisciplinary group composed of childcare assistants, nurse guardians, speech therapist, physiotherapist, psychologist, and pediatricians will develop and implement the educational oral feeding program. They will provide the 2-day theoretical session as well as the three 2-hour practical sessions including reviews of video recording preterm neonates during bottle or breast feedings.~The program will focus on non-nutritive sucking for all neonates from 24 up to 34 weeks' of gestation, early oral feeding from 29 weeks' of gestation and oral stimulation for all preterm neonates admitted to the unit. Additionally, all preterm neonates presenting feeding difficulties symptoms will be evaluated weekly by a physiotherapist or speech therapist.~Each program session is composed of 20 nurses or childcare assistants. Six sessions will be organized in total and all nurses and childcare assistants will be trained
Study: NCT01731431

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Insulin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glyburide
Study: NCT00527527

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: flexion distraction
Description: Chiropractic treatment using the flexion distraction apparatus

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: flexion distraction
Description: Chiropractic treatment using the flexion distraction apparatus

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: flexion distraction
Description: Chiropractic treatment using the flexion distraction apparatus

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo control
Description: Placebo for comparison with flexion distraction treatment
Study: NCT02179385

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Coaching
Study: NCT02091388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY03004
Study: NCT03503968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDG1011
Description: PRAME-T-Cell Receptor Gene Modified Autologous T Cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDG1011
Description: PRAME-T-Cell Receptor Gene Modified Autologous T Cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDG1011
Description: PRAME-T-Cell Receptor Gene Modified Autologous T Cells

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Investigator Choice therapy
Description: Any intervention/therapy chosen by the investigator

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Investigator Choice therapy
Description: Any intervention/therapy chosen by the investigator
Study: NCT00165282

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness training
Description: Taught mindfulness meditation by mindfulness instructor (trained health care professional/RN) and audio c/d
Study: NCT02091388

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperdal® Consta®
Study: NCT00165282

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nurse education
Description: Meets with oncology nurse to have questions answered about medical treatments and side effects
Study: NCT05706558

Intervention type: PROCEDURE
Intervention: Esophagectomy
Description: Esophagectomy
Study: NCT01732666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nefopam
Description: 20 mg of Nefopam mixed in 100 ml of 0.9% saline IV immediately after induction of anesthesia.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: low dose remifentanil
Description: 100 ml of 0.9% saline immediately after anesthesia induction and 0.05µg/kg/min of remifentanil during anesthesia.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: high dose remifentanil
Description: 100 ml of 0.9% saline immediately after anesthesia induction and 0.3 µg/kg/min of remifentanil during anesthesia.
Study: NCT00572468

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: 40 mg of simvastatin

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT01570998

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intraoperative Radiation Therapy
Description: Undergo IORT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03176069

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The physiotherapeutic treatment
Description: The available treatment tools are educational, behavioral and rehabilitating. The physiotherapeutic treatment will consist of the following features:~* Kinesiotherapy~* Manual therapy~* Electrotherapy (electric electrostimulation, ultrasound)~* Behavioral therapy
Study: NCT02633007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVT-301 (levodopa inhalation powder)
Description: Capsules containing l-dopa, designed to deliver ldopa to the lung using the CVT-301 inhaler. CVT-301 will be administered 3 times, 4 hours apart, and 1 hour following the administration of carbidopa.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVT-301 (levodopa inhalation powder)
Description: Capsules containing l-dopa, designed to deliver ldopa to the lung using the CVT-301 inhaler. CVT-301 will be administered 3 times, 4 hours apart, and 1 hour following the administration of carbidopa.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbidopa
Description: Administered orally according to the carbidopa dosing schedule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbidopa
Description: Administered orally according to the carbidopa dosing schedule.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo of CVT-301 is administered in the same way as the investigational product, except that it does not contain l-dopa.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo of CVT-301 is administered in the same way as the investigational product, except that it does not contain l-dopa.
Study: NCT01878357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dihydroartemisinin-piperaquine
Description: Treatment will be given to all malaria-positive individuals on microscopic examination. The dosage will be calculated based on body weight. The drug that will be given is 3-day dihydroartemisinin-piperaquine (DHP) treatment. The drug will be given by health care personnel at their houses assisted by health care volunteers of the integrated health post (Posyandu cadre).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dihydroartemisinin-piperaquine
Description: Treatment will be given to all malaria-positive individuals on microscopic examination. The dosage will be calculated based on body weight. The drug that will be given is 3-day dihydroartemisinin-piperaquine (DHP) treatment. The drug will be given by health care personnel at their houses assisted by health care volunteers of the integrated health post (Posyandu cadre).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: primaquine
Description: One day primaquine (PQ) treatment will be given for P. falciparum infected subjects. For patients who are infected by P. vivax and P. ovale,PQ will be given for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: primaquine
Description: One day primaquine (PQ) treatment will be given for P. falciparum infected subjects. For patients who are infected by P. vivax and P. ovale,PQ will be given for 14 days
Study: NCT04505670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: donepezil orally 5mg
Study: NCT04451109

Intervention type: DEVICE
Intervention: Dilapan-S
Description: Application of Dilapan-S and all other procedures regarding cervical ripening and induction of labor will be carried out as per the hospital's standard practice.
Study: NCT03993288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferrum Lek® (iron (III) hydroxide polymaltosate), 100 mg chewable tablets (Lek d.d., Slovenia)
Description: Participants received Ferrum Lek® 2 tablets daily (200 mg) for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MALTOFER® (iron (III) hydroxide polymaltosate), 100 mg chewable tablets (Vifor S.A., Switzerland)
Description: Participants received MALTOFER® 2 tablets daily (200 mg) for 12 weeks
Study: NCT04141670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S48168
Description: A novel oral small molecule which is designed to repair leaky RYR1 channels

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S48168
Description: A novel oral small molecule which is designed to repair leaky RYR1 channels
Study: NCT03494673

Intervention type: DIAGNOSTIC_TEST
Intervention: BOLD MRI
Description: 1. Prospective End-tidal targeting RespirAct device(A specially designed gas blender and sequential rebreathing circuit) will be used to implement the gas targeting method which involves precise elevations in End-tidal PCO2 while maintaining a fixed End-tidal PO2~2. BOLD MR images will be obtained by using a T2\*-weighted two-dimensional gradient-echo sequence with echoplanar readout.

Intervention type: DIAGNOSTIC_TEST
Intervention: BOLD MRI
Description: 1. Prospective End-tidal targeting RespirAct device(A specially designed gas blender and sequential rebreathing circuit) will be used to implement the gas targeting method which involves precise elevations in End-tidal PCO2 while maintaining a fixed End-tidal PO2~2. BOLD MR images will be obtained by using a T2\*-weighted two-dimensional gradient-echo sequence with echoplanar readout.
Study: NCT01523301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine
Description: Transdermal Patch~Content:~2 mg /24 h (10 cm\^2), 4 mg /24 h (20 cm\^2), 6 mg /24 h (30 cm\^2), 8 mg /24 h (40 cm\^2)~* For early-stage Parkinson's disease, Subjects received Rotigotine patches in escalating weekly dose (starting with daily doses 2 mg/24 h to 8 mg/24 h) for a maximum 4-week Titration Period, then 8 week Maintenance period~* For advanced-stage Parkinson's disease, Subjects received Rotigotine patches in escalating weekly dose (starting with daily doses 4 mg/24 h to 16 mg/24 h) for a maximum 7-week Titration Period, then 8 week Maintenance period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Transdermal Patch~Size:~10 cm\^2, 20 cm\^2, 30 cm\^2, 40 cm\^2~Subjects randomized to placebo received matching placebo patches
Study: NCT00728988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 80mg 12 hours pre-Percutaneous Coronary Intervention (PCI), 40mg 2 hours pre-PCI and 40mg daily after PCI for 30 days.

Intervention type: DRUG
Group type: OTHER
Intervention: Atorvastatin
Description: 40mg daily after PCI for 30 days.
Study: NCT01947257

Intervention type: OTHER
Group type: OTHER
Intervention: the measure TRVMAX
Description: by transthoracic echocardiography

Intervention type: OTHER
Group type: OTHER
Intervention: the measure of the pulmonary artery
Description: by transesophageal ultrasound

Intervention type: OTHER
Group type: OTHER
Intervention: the direct measure of the pulmonary pressures
Description: by right catheterization
Study: NCT01029769

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine or amisulpride
Description: Oral olanzapine 5mg to 20mg/d OR oral amisulpride 200mg to 800mg/d; both preferably once daily, both encapsulated for blinding

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine or amisulpride
Description: Oral olanzapine 5mg to 20mg/d OR oral amisulpride 200mg to 800mg/d; both preferably once daily, both encapsulated for blinding

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine or amisulpride
Description: Oral olanzapine 5mg to 20mg/d OR oral amisulpride 200mg to 800mg/d; both preferably once daily, both encapsulated for blinding

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine or amisulpride
Description: Oral olanzapine 5mg to 20mg/d OR oral amisulpride 200mg to 800mg/d; both preferably once daily, both encapsulated for blinding

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine or amisulpride
Description: Oral olanzapine 5mg to 20mg/d OR oral amisulpride 200mg to 800mg/d; both preferably once daily, both encapsulated for blinding
Study: NCT04505670

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Zinc Oxide
Description: Topical Zinc Oxide 20%
Study: NCT04038255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicoderm C-Q Transdermal Product
Description: 6 weeks of nicotine replacement therapy patches

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicoderm C-Q Transdermal Product
Description: 6 weeks of nicotine replacement therapy patches
Study: NCT04505670

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical Zinc Oxide
Description: Topical Zinc Oxide 20%
Study: NCT01921608

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PrePex™ device
Description: PrePex™ device for adult male circumcision programs. The PrePex™ device is designed to enable conducting male circumcision procedure that is bloodless with no anesthesia and no sutures.
Study: NCT00968747

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fasting
Description: Participants will fast for 72 hours and may consume only water and vitamins.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fasting
Description: Participants will fast for 72 hours and may consume only water and vitamins.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fasting
Description: Participants will fast for 72 hours and may consume only water and vitamins.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: Participants will follow a low-calorie diet until they lose 3-5% of their body weight.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: oral carbohydrate challenge
Description: Participants will fast for 16 hours and then drink a beverage containing glucose, fructose or a mixture of both
Study: NCT04294407

Intervention type: OTHER
Intervention: No intervention
Description: no intervention in this study

Intervention type: OTHER
Intervention: No intervention
Description: no intervention in this study
Study: NCT04038255

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicoderm C-Q Transdermal Product
Description: 6 weeks of nicotine replacement therapy patches

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Orientation session
Description: This session will occur 2 weeks before quit date. It will be moderated by a certified instructor in MT, and will last approximately 90 min. During the session, participants will learn the purpose, format, and procedures of the study, provide electronic informed consent which will be audio-recorded with their permission, and complete the baseline assessment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Orientation session
Description: This session will occur 2 weeks before quit date. It will be moderated by a certified instructor in MT, and will last approximately 90 min. During the session, participants will learn the purpose, format, and procedures of the study, provide electronic informed consent which will be audio-recorded with their permission, and complete the baseline assessment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Craving-to-Quit app
Description: The app is comprised of 22 modules for 22 days, 5-15 minutes each, designed to teach MT using audio, video, and animation. The app also includes other features such as social support (quit friend sign-ups, the tip of the week), activity feed (to track interaction with the app), and my morning stats (to track smoking).
Study: NCT01350362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tideglusib
Description: 1000 mg of tideglusib as a powder for oral suspension once daily in an overnight fasted state for 26 weeks/extension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tideglusib
Description: 1000 mg of tideglusib as a powder for oral suspension once every other day in an overnight fasted state for 26 weeks/extension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tideglusib
Description: 500 mg of tideglusib as a powder for oral suspension once daily in an overnight fasted state for 26 weeks/extension.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Powder for oral suspension administered once daily in an overnight fasted state for 26 weeks/extension.
Study: NCT03196583

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Velo-Lingual Bite (BVL)
Description: The administration of the device will proceed according to both the essential requirements of the European directives concerning medical devices (Annex I and X of directive 93/42/EEC) and the clinical practice standards and guidelines provided by the AASM and AASDM. These include the obtainment of alginate impression of both jaws and an interocclusal record, with the mandible at 50% of its maximal protrusive position. Since no single standard titration protocol is available, progressive mandibular advancement will be conducted according to the best available medical standard.
Study: NCT00979654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sifalimumab
Description: All participants will receive intravenous (IV) sifalimumab as fixed dose of 500 mg every 2 weeks (Q2W) on Day 1, Week 2, and Week 4, then every 4 weeks (Q4W) thereafter for a total of 156 weeks. The initial fixed dose of 500 mg is increased to 600 mg with subsequent protocol amendment.
Study: NCT01532934

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: motivational enhancement therapy
Description: Four 45-minute MET sessions

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: standard care
Study: NCT03262428

Intervention type: OTHER
Intervention: Semi-structured interviews
Description: Patients, caregivers and health care professionals involved in self-management support will be sought via patient organizations and professional organizations in the region. Study information materials will be provided to these organizations for dissemination to their members, providing also contact details of the study team for interested individuals to register their interest and provide basic eligibility and screening information. Selected participants will be invited to take part in a face-to-face or telephone interview about (supporting) self-management. Data collection will consist of semi-structured interviews conducted either face-to-face or by telephone.

Intervention type: OTHER
Intervention: Semi-structured interviews
Description: Patients, caregivers and health care professionals involved in self-management support will be sought via patient organizations and professional organizations in the region. Study information materials will be provided to these organizations for dissemination to their members, providing also contact details of the study team for interested individuals to register their interest and provide basic eligibility and screening information. Selected participants will be invited to take part in a face-to-face or telephone interview about (supporting) self-management. Data collection will consist of semi-structured interviews conducted either face-to-face or by telephone.

Intervention type: OTHER
Intervention: Semi-structured interviews
Description: Patients, caregivers and health care professionals involved in self-management support will be sought via patient organizations and professional organizations in the region. Study information materials will be provided to these organizations for dissemination to their members, providing also contact details of the study team for interested individuals to register their interest and provide basic eligibility and screening information. Selected participants will be invited to take part in a face-to-face or telephone interview about (supporting) self-management. Data collection will consist of semi-structured interviews conducted either face-to-face or by telephone.